{"filing":{"accession_number":"0001175680-26-000038","cik":"0001175680","ticker":"CYDY","company_name":"CytoDyn Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-16","primary_document":"ck0001175680-20261016.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1175680/000117568026000038/ck0001175680-20261016.htm"},"events":[{"id":36149,"run_id":33328,"accession_number":"0001175680-26-000038","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.94,"summary":"Robert E. Hoffman was appointed Chief Executive Officer of CytoDyn effective October 20, 2026, following Board approval on October 16, 2026, replacing Dr. Jacob Lalezari who transitioned to Head of Research and Translational Sciences. The appointment includes significant compensation changes, including a base salary increase to $525,000, bonus target increase to 50%, and a 2.5 million share option grant, representing a material executive leadership transition for the clinical-stage biopharmaceutical company.","company_name":"CytoDyn Inc.","ticker":"CYDY","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40463,"accession_number":"0001175680-26-000038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Robert E. Hoffman was appointed Chief Executive Officer of CytoDyn effective October 20, 2026, following Board approval on October 16, 2026. While Dr. Jacob Lalezari's concurrent resignation as CEO and transition to Head of Research and Translational Sciences also occurred, the principal disclosed action centers on the appointment of a new CEO with significant compensation changes (base salary increase to $525,000, bonus target increase to 50%, and a 2.5 million share option grant). This is a material executive leadership transition for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:52:41.206068+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40464,"accession_number":"0001175680-26-000038","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces the appointment of Robert E. Hoffman as Chief Executive Officer, effective October 20, 2026, replacing Dr. Jacob Lalezari who transitions to a scientific role. The press release (EX-99.1) explicitly states \"CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer\" and details his extensive biotech executive background. This is a material executive appointment at a clinical-stage company preparing for a critical phase of clinical development and regulatory milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:52:41.206068+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40463,"accession_number":"0001175680-26-000038","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Robert E. Hoffman was appointed Chief Executive Officer of CytoDyn effective October 20, 2026, following Board approval on October 16, 2026. While Dr. Jacob Lalezari's concurrent resignation as CEO and transition to Head of Research and Translational Sciences also occurred, the principal disclosed action centers on the appointment of a new CEO with significant compensation changes (base salary increase to $525,000, bonus target increase to 50%, and a 2.5 million share option grant). This is a material executive leadership transition for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:52:41.206068+00:00","company_name":"CytoDyn Inc.","ticker":"CYDY","filing_date":"2026-10-19"},{"id":40464,"accession_number":"0001175680-26-000038","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces the appointment of Robert E. Hoffman as Chief Executive Officer, effective October 20, 2026, replacing Dr. Jacob Lalezari who transitions to a scientific role. The press release (EX-99.1) explicitly states \"CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer\" and details his extensive biotech executive background. This is a material executive appointment at a clinical-stage company preparing for a critical phase of clinical development and regulatory milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:52:41.206068+00:00","company_name":"CytoDyn Inc.","ticker":"CYDY","filing_date":"2026-10-19"}]}